AIA Group Ltd Has $3.97 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

AIA Group Ltd grew its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 25.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 24,367 shares of the company's stock after acquiring an additional 4,983 shares during the period. AIA Group Ltd's holdings in Zoetis were worth $3,970,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of ZTS. Norges Bank acquired a new position in shares of Zoetis during the 4th quarter worth $824,321,000. Wellington Management Group LLP raised its holdings in Zoetis by 78.5% during the fourth quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock valued at $1,133,755,000 after buying an additional 3,059,255 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Zoetis during the 4th quarter worth about $196,651,000. Polen Capital Management LLC increased its holdings in shares of Zoetis by 17.5% during the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company's stock valued at $1,219,237,000 after acquiring an additional 1,116,541 shares during the last quarter. Finally, Amundi raised its stake in shares of Zoetis by 46.2% in the 4th quarter. Amundi now owns 2,748,719 shares of the company's stock valued at $453,355,000 after acquiring an additional 867,993 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares of the company's stock, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock worth $312,254 over the last three months. Company insiders own 0.16% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. UBS Group assumed coverage on Zoetis in a report on Monday, December 9th. They set a "neutral" rating and a $196.00 price target on the stock. Barclays raised their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Piper Sandler boosted their target price on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Stifel Nicolaus cut their price objective on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Finally, StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $215.90.

Zoetis Price Performance

Shares of ZTS stock traded down $3.76 during mid-day trading on Thursday, reaching $159.74. The company's stock had a trading volume of 2,243,293 shares, compared to its average volume of 2,598,407. The firm's 50-day moving average is $166.20 and its two-hundred day moving average is $173.98. The company has a market cap of $71.53 billion, a P/E ratio of 29.25, a PEG ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts' consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.25%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.